Positron Corporation

Positron Corporation

POSC
Positron CorporationUS flagOther OTC
1.90
USD
-0.02
- -
27.12MMarket Cap
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
2024 Y
2025 Y
TTM
Revenue per Share
20.91
4.69
10.86
13.81
6.32
2.42
2.59
3.39
0.89
0.45
0.16
0.02
0.01
0.09
Basic EPS, GAAP
-12.47
-23.41
-32.32
-32.46
-26.68
-9.62
-6.12
-3.11
-2.51
-1.96
-0.28
-0.09
-0.34
-0.09
Free Cash Flow per Basic Share
-9.87
-13.79
-10.13
-14.7
-10.17
-5.63
-2.76
-2.08
-0.73
-0.84
-0.26
-0.07
-0.16
-0.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-435.46
-377.97
-333.53
-315.32
-249.64
-146.29
-53.12
-51.26
-32.29
-30.08
-13.55
-5.17
-4.69
-8.96
Tangible Book Value per Share
-18.04
-25.47
-37.83
-47.4
-39.69
-23.41
-3.94
-5.58
-3.11
-4.04
-0.17
-0.05
0.05
-0.16
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
2
2
3
4
9
26
31
14
Sales/Revenue/Turnover
3
1
2
3
2
1
5
7
3
2
1
1
- -
1
Operating Margin (%)
-54.03
-400.52
-172.3
-217.95
-238.1
-333.96
-312.44
-65.92
-168.58
-204.79
-187.11
-375.32
-2,275.09
-126.76
Depreciation Expense
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-4
-7
-8
-9
-6
-11
-6
-8
-7
-3
-2
-11
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-59.64
-499.48
-297.61
-235.12
-422.15
-397.58
-236.28
-91.87
-284.01
-435.83
-176.26
-404.95
-2,297.83
-102.67
Working Capital
-1
-2
1
-2
-6
-7
- -
-3
-7
-12
-2
-1
1
-3
LT Debt
2
1
- -
- -
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
Total Equity
-2
-3
-1
-5
-7
-7
- -
-3
-6
-11
-1
-1
1
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
1
1
1
Shares Outstanding
14
14
14
Market Capitalization
9
8
3

Working Capital

FRC

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
3
Payables & Accruals
1
1
1
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
321.86%
-47.3%
-319.85%
Free Cash Flow
21.23%
23.38%
177.28%
Net Income, GAAP
33.7%
58.68%
345.69%
Sales/Revenue/Turnover
5.44%
-38.24%
-21.45%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
-0.03
-0.02
- -
-0.09
2025
-0.05
- -
- -
- -
-0.34
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Adel Abdullah
Full Time Employees
19
Sector
Healthcare
Industry
Medical - Devices
Address
1777 Maryland Avenue Niagara Falls NY United States of America 14305
IPO Date
Aug 9, 1999
Business
Positron Corporation Positron Corporation (POSC) develops, manufactures, and sells state-of-the-art positron emission tomography (PET) and PET-CT molecular imaging systems focused primarily on cardiac diagnostics, along with related clinical services and support solutions; its core products include the Attrius cardiac PET system, which features software for coronary artery overlay display, motion correction, and customizable protocols; the NeuSight PET-CT 64-slice scanner, offering advanced imaging for cardiology practices with reduced scan times and higher diagnostic accuracy compared to SPECT; PosiRx, an automated system for radiopharmaceutical preparation and delivery; and the forthcoming Affinity-CT4D 64-slice system targeting both cardiac and oncology imaging markets. The company provides turnkey solutions encompassing equipment acquisition, installation, staff training, isotope supply, and customer care plans like PosiStar, serving nuclear cardiologists, private practices, and healthcare providers seeking gold-standard cardiac disease detection and improved patient outcomes. Founded in 1983 and headquartered in Niagara Falls, New York, Positron operates principally in the United States, with technology co-development through its partnership with Shenyang Intelligent Nuclear Technology Co., a Neusoft Medical Systems subsidiary. In recent developments, Positron established a new corporate headquarters in the Niagara Falls area under a long-term lease in August 2025 to support growth, product showcase, and operational expansion; redomiciled from Texas to Delaware to enhance governance ahead of filing a Form 10 for SEC fully reporting status in November 2025; secured $8 million in funding for market expansion; entered an industry partnership with MedAxiom in October 2025; signed an OEM supply and distribution agreement for the NeuSight PET-CT; and partnered with Upbeat Cardiology Solutions in November 2024 to broaden access to PET-CT systems via leasing, purchasing, and comprehensive support services for cardiology practices nationwide.

Company News

APIChat
  • Head-To-Head Review: Positron (OTCMKTS:POSC) versus Pressure BioSciences (OTCMKTS:PBIO)

  • Contrasting Positron (OTCMKTS:POSC) and AngioDynamics (NASDAQ:ANGO)

  • Positron Corporation Secures Multiple PET-CT Orders from Leading Nuclear Cardiologist Practices

  • Reviewing Positron (OTCMKTS:POSC) and Tenon Medical (NASDAQ:TNON)

  • OPKO Health (NASDAQ:OPK) & Positron (OTCMKTS:POSC) Head-To-Head Review

  • Positron Corporation Announces Its Transition to a Reporting SEC Company

  • Positron Corporation Enters Industry Partnership Agreement with MedAxiom

  • Positron Corporation Wins Innovation Award in PET-CT Category from Medical Device Network's Excellence Awards 2025

  • Positron Corporation Announces New Corporate Headquarters and Strategic Redomiciling to Delaware

  • Positron Corporation Secures Multi-Unit Sale of PET-CT Scanners to Leading Cardiology Group

  • Positron (OTCMKTS:POSC) Shares Up 0.2% – Still a Buy?

  • Positron Corporation Expands Market Presence with Sale of NeuSight PET-CT Scanner

  • Positron Corporation Secures Agreement to Sell Four PET-CT Scanners

  • Positron Corporation Secures $8 Million in Capital to Accelerate Growth and Market Expansion

  • Positron Corporation Secures Agreement for Three NeuSight PET-CT 64 Slice Scanners

  • AI chip startup Positron raises $23.5 million seed round to take on Nvidia

  • AI Hardware Industry Veteran Mitesh Agrawal Joins Positron as CEO—A Startup Aiming to Challenge Nvidia's Grip on AI Infrastructure

  • Positron Corporation Announces Sale of Attrius PET and NeuSight PET-CT Scanners

  • Positron Corporation Secures Agreement to Sell and Rent Eight NeuSight PET-CT Scanners

  • Actineer Appoints Radiopharmaceutical Executive Joseph Oliverio as President and CEO